Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial.

Date publication

janvier 2017

Journal

PloS one

Auteurs

Membres identifiés du Cancéropôle Est :
Pr CONROY Thierry , Dr LAMBERT Aurélien

Tous les auteurs :
Lambert A, Jarlier M, Gourgou Bourgade S, Conroy T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28931010

Résumé

Hohla et al. suggested that female gender could positively predict response to FOLFIRINOX in patients with advanced pancreatic cancer. In this study, we explored the response to the FOLFIRINOX regimen by gender within the trial PRODIGE4/ACCORD 11.

Mots clés

Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, CA-19-9 Antigen, analysis, Deoxycytidine, analogs & derivatives, Disease-Free Survival, Female, Humans, Liver Neoplasms, secondary, Lung Neoplasms, secondary, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Staging, Pancreatic Neoplasms, drug therapy, Prognosis, Proportional Hazards Models, Quality of Life, Sex Factors, Survival Rate

Référence

PLoS ONE. 2017 ;12(9):e0183288